1
February 2024
Genflow
Biosciences Plc
("Genflow" or "the Company")
Genflow Biosciences Releases
2023 Year-End Review and Highlights Key Priorities for
2024
The Company (LSE:GNF) (OTCQB:GENFF),
an emerging leader in the field of longevity research developing
therapeutics that potentially halt or slow the ageing process, is
pleased to provide a year-end review and summary of its progress
during 2023 and defined strategic priorities for 2024.
The Company achieved many significant
accomplishments throughout the year across all aspects of its
business. The full year-end review can be viewed on Genflow's
website:
https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.
Key
2023 Highlights:
·
Genflow expanded its intellectual property
portfolio with a provisional patent application for editing the
SIRT6 gene, linked to longevity and age-related
diseases.
·
Began trading on the OTCQB Venture Market in the
US under the ticker GENFF, aligned to its US-focused
strategy.
·
Genflow received positive feedback from the
Federal Agency for Medicines and Health Products in Belgium on the
design of Phase I/II clinical trials for its lead drug candidate,
GF-1002, in NASH patients.
·
Genflow made several key appointments, including
Capital Plus Partners Ltd as Joint Broker in order to access both
institutional and international investment; Harbor Access for
investor relations support; and Prof. Dr. Sven Francque, an expert
in nonalcoholic fatty liver disease and Prof. Dr. Mary E. Rinella,
a fatty liver disease specialist to its Scientific Advisory
Board.
Strategic Priorities in 2024:
·
Genflow awarded 2.89 million Euros in two new
grants that will broaden its research pipeline and expand the size
of its therapeutic markets over the next three years. (Refer to
press release: https://www.globenewswire.com/news-release/2024/01/18/2811445/0/en/Genflow-Biosciences-Partners-with-Revatis-SA-and-EXO-Biologics-in-Groundbreaking-Aging-Research-Fueled-by-Two-Major-Research-Grants.html)
·
Genflow to undertake key Investigational New Drug
(IND)-enabling development activities that will help define the
pharmacological and toxicological properties of its lead drug
candidate, GF-1002, and its potential benefits for NASH
patients.
·
Initial site selection and QMS framework for
clinical readiness, expected by the end of 2025 for the NASH
program.
·
Commence preliminary discussions with the European
Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan
Drug Application (ODA) for our second compound
GF-3001, targeting Werner Syndrome.
·
Select Contract Development and Manufacturing
Organization (CDMO) for advancing the GMP
manufacturing of the NASH clinical lot of lead
drug candidate, GF-1002.
·
Develop and implement project management,
budgeting and governance for collaborative partners, in line with
clinical and pre-clinal activities that will enable IND
applications.
·
Moving key patent applications under the Patent Cooperation
Treaty (PCT) to the national phase, while further
expanding our development pipeline with new products and new
indications.
Dr. Eric Leire, CEO of Genflow
commented: "The milestones we reached in 2023 were numerous, and I
commend our team for their exceptional commitment to execution and
delivery. While 2023 was a pivotal year, we're poised for an even
stronger 2024, as we shift focus to scaling development of our lead
drug candidate, GF-1002, and its potential benefits for NASH
patients. With the support of our partners and the backing of new
grants, we are poised to make meaningful advancements in the field
of longevity."
Contacts
Genflow Biosciences
|
Harbor Access
|
Dr Eric Leire, CEO
|
Jonathan Paterson, Investor
Relations
|
+32-477-495-881
|
+1 475 477 9401
|
|
Jonathan.Paterson@Harbor-access.com
|
|
|
Joint Corporate Brokers
|
|
Clear Capital Markets
|
Capital Plus Partners Ltd
|
Bob Roberts, +44 203 869
6080
|
Dominic Berger, +44 203 821
6167
|
|
Keith Swann, +44 0203 821
6169
|
|
Jon Critchley, +44 0203 821
6168
|
|
|
About Genflow Biosciences
Established in 2020, Genflow
Biosciences Ltd is a UK-based biotechnology company, with R&D
facilities in Belgium, developing and researching potential novel
therapeutics that halt or slow the ageing process enabling society
to live longer, healthier lives. Genflow Biosciences' lead compound
GF-1002 works through the delivery of a centenarian variant of the
SIRT6 gene, which has yielded promising preclinical results.
Genflow Biosciences expects to commence a clinical trial in 2024 to
study the potential benefit of GF-1002 in non-alcoholic
steatohepatitis (NASH) for which there are few or no approved
therapies. By treating ageing as a risk factor to disease, Genflow
Biosciences aims to reduce the financial, emotional, and social
costs of an ageing population. For more information:
www.genflowbio.com
DISCLAIMER
The contents of this announcement
have been prepared by, and are the sole responsibility of, the
Company.
This announcement may contain
forward-looking statements. The forward-looking statements
include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or
strategies regarding the future. In addition, any statement that
refers to projections, forecasts or other characterisations of
future events or circumstances, including any underlying
assumptions, is a forward-looking statement. The words
"anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential",
"predict", "project", "seek", "should", "would" and similar
expressions, or in each case their negatives, may identify
forward-looking statements, but the absence of these words does not
mean that a statement is not forward-looking.
Forward-looking statements include
all matters that are not historical facts. Forward-looking
statements are based on the current expectations and assumptions
regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the
future, by their nature, they are subject to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict. Forward-looking statements are not guarantees
of future performance and the Company's actual financial condition,
actual results of operations and financial performance, and the
development of the industries in which it operates or will operate,
may differ materially from those made in or suggested by the
forward-looking statements contained in this announcement. In
addition, even if the Company's financial condition, results of
operations and the development of the industries in which it
operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or
developments may not be indicative of financial condition, results
of operations or developments in subsequent periods. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include regional, national
or global, political, economic, social, business, technological,
competitive, market and regulatory conditions.
Any forward-looking statement
contained in this announcement applies only as of the date of this
announcement and is expressly qualified in its entirety by these
cautionary statements. Factors or events that could cause the
Company's actual plans or results to differ may emerge from time to
time, and it is not possible for the Company to predict all of
them. The Company expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in
its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in
this announcement is based, unless required to do so by applicable
law, the Prospectus Regulation Rules, the Listing Rules, the
Disclosure Guidance and Transparency Rules of the FCA or the UK
Market Abuse Regulation.